Antibody-Drug Conjugate MIRV Improves OS in Ovarian Cancer

In the phase 3 MIRASOL study, the antibody-drug conjugate MIRV produced an overall survival benefit in women with platinum-resistant ovarian cancer.
MDedge News

source https://www.medscape.com/viewarticle/992769?src=rss